CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim an…
DOI 10.1055/s-0044-1789726
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB. Siegmund, S. Danese, L. Peyrin-Biroulet, M. Dubinsky, P. Dulai, H. Tilg, S. Sloan, C. Rabbat, B. Sands, S. Vermeire
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2024
Jahrgang / SeitenJg. 62 · S. e625-e626
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis
Zitieren
Zitierempfehlung
B. Siegmund, S. Danese, L. Peyrin-Biroulet, M. Dubinsky, P. Dulai, H. Tilg, S. Sloan, C. Rabbat, B. Sands, S. Vermeire (2024) Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis. Zeitschrift für Gastroenterologie, 62 (09), e625-e626. https://doi.org/10.1055/s-0044-1789726
Mit CareLit weiterarbeiten